RACHEL KOLLER: Open Payments
NPI 1093552655 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$649 in 18 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $579 · 2025 $649
Food & beverage: $649
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 5 | $268 |
| Lilly USA, LLC | 4 | $104 |
| AstraZeneca Pharmaceuticals LP | 2 | $66 |
| Syndax Pharmaceuticals, Inc. | 2 | $58 |
| Celgene Corporation | 1 | $34 |
| ABBVIE INC. | 1 | $33 |
| SOBI, INC | 1 | $31 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Merck Sharp & Dohme LLC | 1 | $26 |
Products named: Xospata, JAYPIRCA, Cresemba, CALQUENCE, REBLOZYL, EPKINLY, Gamifant, Vanflyta.
Industry payments across TX — which companies pay providers there.
